After the Comprehensive Economic Cooperation Agreement signed between India and Australia, the domestic pharmaceutical industry is seeing a plethora of opportunities for international trade.
On farmers and food, vaccine inequality, climate justice and digital rights, we need to act in solidarity – and not allow trade rules to sacrifice people to corporate profit.
Even without an IP waiver from the WTO, China and India are leading the challenge to the West’s vaccine monopoly.
Talks on a possible COVID-19-related TRIPS decision aimed at scaling up vaccine and therapeutics production and equitable distribution continue but investment agreements are absent from them.
There is evidence of a potential conflict between the CPTPP and the UK’s current system of market authorisation of generic and biosimilar drugs.
Heesob Nam, a patent attorney who dedicated his life to preventing the monopoly of ’intellectual property’ by a few, passed away on May 10th.
Potential BIT claims by foreign pharmaceutical companies against India for the revocation, suspension or non-enforcement of IPRs could undermine the benefits of a potential TRIPS waiver.
The COVID-19 pandemic, and the race to make vaccines and other useful technologies more accessible to people around the world, has once again highlighted the tension between intellectual property rights and the promotion of public health.
They have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
People around the world need to be aware of precedents in recent trade agreements and ensure that they also work for access to medicines for their own citizens.
Vietnam seeks to build on its new free trade agreement with the European Union to expand foreign investment in medical equipment and pharmaceuticals, with the government position the country as an alternative production base to China.
India is seeking concessions for generic drugs it exports to the United States in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal.
The union and its allies also asked the government not to join the Trans-Pacific Partnership, as they view that the restriction of rights to access medicine under the deal would put the country’s public health system in danger.
The US trade model is not only unpopular with the British public, but it will also make us more vulnerable to future pandemics.
In order to halt the spread of the coronavirus pandemic (Covid-19) and to boost the public health care system and preparedness, India has taken several regulatory steps.
The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
Donald Trump will put the interests of corporate America first and demand that the NHS pays higher prices for US drugs in a free-trade deal with the UK, the outgoing British ambassador to Washington said.
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."